AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01828255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish®
Study NCT01118728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02410252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iThermonitor
Description: The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
Study NCT02972411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary ventilatory response
Description: Training of the subjects for voluntary increase in the respiratory minute ventilation
Study NCT02972411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
Study NCT02611284 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
Study NCT02611284 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: INSURE
Description: The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients.
Study NCT04180345 — intervention group
Intervention type: OTHER
Intervention: Psychometric validation of the questionnaire
Description: Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)
Study NCT00542009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
Study NCT01125995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: early CCRT
Description: 1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy).
Study NCT01125995 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: late CCRT
Description: 1. patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 \& Cisplatin 70mg/m2 D1.~2. radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy).
Study NCT00447603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (+) losartan potassium
Description: losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
Study NCT00447603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
Study NCT00542009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CE-326,597 5mg QD
Description: Administered orally, once daily with morning meal for duration of trial (84 days).
Study NCT00447603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Losartan
Study NCT04306965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 30 mg twice daily (BID)
Study NCT03839862 — intervention group
Intervention type: DRUG
Intervention: TNF-inhibition
Description: Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
Study NCT04574908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViSi device
Description: Mobile patient monitoring system for vital signs.
Study NCT04574908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViSi device
Description: Mobile patient monitoring system for vital signs.
Study NCT04234139 — intervention group
Intervention type: PROCEDURE
Intervention: liver transplant
Description: solid organ transplant
Study NCT01398969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh FMT
Description: Participants will receive fresh FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
Study NCT01398969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Frozen-and-Thawed FMT
Description: Participants will receive frozen-and-thawed FMT (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat FMT will be performed
Study NCT00521638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRU-015
Description: Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
Study NCT02657122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
Study NCT02657122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
Study NCT02657122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
Study NCT02657122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
Study NCT03883230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GLYWD
Description: As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
Study NCT01511029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 300 mg - Oral Tablets
Study NCT01511029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: 600 mg Oral Tablets
Study NCT01511029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexpramipexole Placebo
Description: Placebo - Oral Tablet
Study NCT01511029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg - Oral Tablet
Study NCT02132182 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood draw
Description: The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
Study NCT02559752 — intervention group
Intervention type: OTHER
Intervention: NIH Toolbox Cognitive Battery
Description: * For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~* For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning.
Study NCT01970982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS 2.2)
Description: THS 2.2 ad libitum for 5 days in confinement
Study NCT01970982 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Smoking abstinence (SA)
Description: SA for 5 days in confinement
Study NCT01970982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette (CC)
Description: Subject's own preferred brand of CC ad libitum for 5 days in confinement
Study NCT03270605 — intervention group
Intervention type: PROCEDURE
Intervention: Myomectomy
Description: Surgical removal of uterine fibroid
Study NCT02565043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RENASYS TOUCH Negative Pressure Wound Therapy System
Description: RENASYS TOUCH NPWT System was administered to all participants.
Study NCT02565043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RENASYS TOUCH Negative Pressure Wound Therapy System
Description: RENASYS TOUCH NPWT System was administered to all participants.
Study NCT01310387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active pain management
Description: Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
Study NCT01358695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.
Study NCT01358695 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ANT-1207
Description: The interventions differ by dose of investigational product applied.
Study NCT01358695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: The interventions differ by dose of investigational product applied.
Study NCT01358695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.
Study NCT01358695 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: The interventions differ by dose of investigational product applied.
Study NCT01191164 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation Utilizing Permanent Breast Seed Implant
Description: Target Volumes: The surgical cavity will be assessed with US \& CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre.
Study NCT01984684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin
Study NCT01984684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Study NCT01984684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aztreonam
Study NCT01175603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)
Description: 6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
Study NCT02707835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self massage
Description: self massage, skin care education, manual lymph drainage exercise, compression garment
Study NCT02707835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual lymph drainage
Description: manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
Study NCT02707835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: epidermis fascia taping
Description: epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
Study NCT03152526 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interventions
Description: CliniMACS® CD3 and CD19 Reagent System
Study NCT02371954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy Older Latinos are Active
Description: Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
Study NCT02371954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fotonovela
Description: Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
Study NCT04310592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-001
Description: CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
Study NCT03271281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One injection of 68Ga-NODAGA-E[c(RGDyK)]2
Description: One injection of 68Ga-NODAGA-E\[c(RGDyK)\]2
Study NCT03271281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Following injection of 68Ga-NODAGA-E\[c(RGDyK)\]2 the patients will be subjected to whole body PET/CT
Study NCT02218437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC+ATG
Description: MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
Study NCT02395042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study NCT02395042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS®
Description: LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
Study NCT02395042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS Placebo
Description: LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
Study NCT02040051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sound isolation / Music therapy
Description: Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)
Study NCT01861899 — intervention group
Intervention type: DEVICE
Intervention: SI-LOK
Description: Sacro-iliac joint fusion
Study NCT00447603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Losartan/HCTZ
Description: losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
Study NCT00655421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided Visual Inspection
Description: Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
Study NCT00655421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelScope
Description: Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
Study NCT00655421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toluidine Blue Assisted Oral Examination
Description: Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
Study NCT03721939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEX Scoring Catheter
Description: Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
Study NCT04435366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacincaptad Pegol
Description: Avacincaptad Pegol Intravitreal Injection
Study NCT04435366 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Administration (includes placement of the blunt opening of an empty, needleless syringe barrel on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection)
Study NCT03696017 — intervention group
Intervention type: OTHER
Intervention: Multi-domain assessment battery
Description: Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.
Study NCT03853109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
Study NCT03575325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
Study NCT00321711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
Study NCT00321711 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 531 (Romiplostim)
Description: AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
Study NCT00321711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: hypomethylating agent
Study NCT00321711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: hypomethylating agent
Study NCT00321711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: hypomethylating agent
Study NCT00321711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Decitabine
Description: hypomethylating agent
Study NCT04211298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be used for sedation during bronchoscopy
Study NCT04211298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol
Study NCT04398303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACT-20-MSC
Description: 1 million cells / kg body weight in 100 ml in conditioned media
Study NCT04398303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACT-20-CM
Description: 100 ml of conditioned media only
Study NCT04495179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: Subjects will receive AZD4635 orally daily
Study NCT04495179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.
Study NCT04495179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Subjects will receive intravenous cabazitaxel every 3 weeks
Study NCT03707977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART
Description: ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.